SEPOY.net
No Result
View All Result
Wednesday, July 16, 2025
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
No Result
View All Result
SEPOY.NET
No Result
View All Result
Home Health

Study confirms efficacy of molnupiravir against COVID in a real-life cohort

Nicholas by Nicholas
July 27, 2022
in Health
0

Since the onset of the coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), over 6.38 million deaths and 572 million infections have been reported.

READ ALSO

UK Biobank completes world's largest whole-body imaging project

Virtual eye clinics in shopping centers cut waiting times for routine appointments

Due to genomic mutations, many SARS-CoV-2 variants have emerged with varied virulence and transmission rates as compared to the ancestral SARS-CoV-2 strain. These variants have been classified as variants of concern (VOC) and variants of interest (VOI) by the World Health Organization (WHO). At present, the SARS-CoV-2 Omicron (B.1.1.529) variant is the dominant circulating strain in most countries around the world. This variant appears to have a short incubation period of two to 11 days. 

Study: Safety and efficacy of molnupiravir in SARS-CoV-2 infected patients: a real-life experience. Image Credit: Quality Stock Arts / Shutterstock.com

Background

Some of the common symptoms associated with COVID-19 include cough, fever, gastrointestinal disorders, dyspnea, headache, as well as loss of smell and taste. In some cases, individuals who experience severe COVID-19 may suffer life-threatening systemic inflammation, multiorgan dysfunction, and respiratory failure. 

Various pharmaceutical and non-pharmaceutical strategies have been developed to combat COVID-19. In terms of pharmaceutical approaches, several vaccines and therapeutics have been developed and have subsequently received approval from global regulatory bodies, such as the United States Food and Drug Administration (FDA).

Previous in vitro and in vivo studies have shown that molnupiravir, which is a ribonucleoside prodrug of N-hydroxycytidine (NHC), is effective against SARS-COV-2. Molnupiravir, which targets the ribonucleic acid (RNA)-dependent RNA polymerase (RdRp) of SARS-CoV-2, is associated with a superior safety profile. 

One of the key advantages of molnupiravir for the treatment of COVID-19 is that it can be easily administered at home. Other COVID-19 therapeutics, such as monoclonal antibodies and remdesivir, require hospital settings to be administered.

Phase II clinical studies have determined the most effective dose of molnupiravir to be 800 mg every 12 hours for five days. However, there remains a lack of real-life data confirming the efficacy of molnupiravir in treating COVID-19.

About the study

In a recent retrospective Journal of Medical Virology study, researchers report the efficacy and safety of molnupiravir in a real-life setting.

The study cohort included adult participants diagnosed with COVID-19, which was confirmed by the reverse transcription-polymerase chain reaction (RT-PCR) assay. These patients were subjected to a five-day treatment course with molnupiravir according to the Italian Agency for Drugs guidelines.

Symptomatic COVID-19 patients who did not require oxygen supplementation and were not at risk of developing severe symptoms due to the presence of comorbidities were prescribed molnupiravir. The medical history, blood test results, and other relevant documents were reported for all study participants, regardless of disease progression. Furthermore, the researchers calculated the Charlson Comorbidity Index (CCI) score and 4C-score for the study cohort.

Study findings

The current study included 192 people whose mean age was 70.4 years. In the study cohort, 144 patients were above 40 years of age.

During follow-up, 10.4% of participants exhibited disease progression. Notably, neurodegenerative disorders were associated with an increased risk of COVID-19 progression. 

Multivariate analysis revealed older age individuals with neurological disease who exhibited dyspnea at the onset of symptoms and acquired COVID-19 during a hospital stay for another health condition were associated with an increased risk of disease progression. 

Importantly, molnupiravir was found to be effective in older people who were not vaccinated against COVID-19. The early initiation of molnupiravir therapy was associated with a reduced risk of disease progression. Importantly, 6.8% of the study cohort exhibited adverse effects of the drug, thus confirming the overall safety of this treatment.

Conclusions

The current study highlights the effectiveness and safety of molnupiravir in a real-life setting, particularly among an elderly population with a high incidence of comorbidities.

Some limitations of the current study include its observational and retrospective approach. Further, the cohort does not represent an international situation. CT scans and blood tests were also not acquired for the entire study cohort.

In the future, more studies are needed to determine the optimal timing to start molnupiravir treatment in COVID-19 patients.

Journal reference:

  • De Vito, A., Colpani, A., Bitti, A., et al. (2022). Safety and efficacy of molnupiravir in SARS-CoV-2 infected patients: a real-life experience. Journal of Medical Virology.  doi:10.1002/jmv.28011.

Tags: Antiviral DrugBloodCoronavirusCoronavirus Disease COVID-19CoughDyspneaEfficacyGenomicHospitalOmicronPandemicPolymeraseRespiratoryRNASARSSARS-CoV-2Severe Acute RespiratorySevere Acute Respiratory SyndromeSyndromeTherapeutics

Related Posts

UK Biobank completes world's largest whole-body imaging project
Health

UK Biobank completes world's largest whole-body imaging project

July 16, 2025
Virtual eye clinics in shopping centers cut waiting times for routine appointments
Health

Virtual eye clinics in shopping centers cut waiting times for routine appointments

July 16, 2025
New UAB-developed gene therapy for ALS receives orphan drug designation
Health

New UAB-developed gene therapy for ALS receives orphan drug designation

July 15, 2025
Research explains how low sodium weakens the heart’s electrical signals
Health

Research explains how low sodium weakens the heart’s electrical signals

July 15, 2025
OMED Health launches new gastrointestinal treatments and services through personalized Health Plans
Health

OMED Health launches new gastrointestinal treatments and services through personalized Health Plans

July 15, 2025
New cellular entry pathway improves gene therapy outcomes
Health

New cellular entry pathway improves gene therapy outcomes

July 15, 2025
Next Post

Ukraine live ticker: Economic researchers warn of a deep recession

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

About

Sepoy.net is a perfect place for people who want daily updates on news related to business, technology, entertainment, health, cryptocurrency etc.

Contact: hello@sepoy.net

Major Categories

News

Business

Tech

Economy

 

Recent Posts

  • So abhelfen Die leser Probleme, sofern Die leser gar nicht nach die bestimmte Blog zugreifen book of ra tricks spielothek beherrschen
  • Spartacus: Call To help you Fingers Slot Comment
  • Champion play santas wild ride Raceway Slot: Claim Around 2 hundred Free Revolves

Pages

  • About Us
  • Contact Us
  • Disclaimer
  • DMCA
  • Home
  • Privacy Policy

© 2023 Sepoy.net

No Result
View All Result
  • Home
  • Business
  • News
  • Health
  • Tech
  • Science
  • Lifestyle
  • Travel

© 2023 Sepoy.net